Heterogeneity of treatment benefit
asthma, exacerbations
ASTHMA
Figure 
Lorenz curve for the heterogeneity of treatment benefit comparing 75 mg mepolizumab versus placebo in severe asthma. Left panel, predicted reduction in rate of severe exacerbations in 365 days of follow up. Right panel, predicted reduction in ACQ5 scores in 365 days of follow up. The Gini Index captures the level of inequality in predicted treatment benefitFigure 
Averaged treatment effect comparing mepolizumab 75 mg versus placebo in severe asthma across quintiles of predicted treatment benefit. Left panel, observed treatment benefit in terms of average reduction in the rate of severe exacerbations per year; Right panel, observed treatment benefit in terms of average reduction in ACQ5 scoresOf note, covariates in combination outperformed the capacity of any single predictor. For example, consider BEC as a single biomarker to predict treatment benefit, which was a most important predictor for treatment response to both exacerbation and symptom control (Fig. 